Affinity Asset Advisors, LLC — Full 13F Portfolio Breakdown

Diversified strategySector-focusedMomentum follower

Total reported value

$1.9B

Reporting period: 2026-03-31 · Number of holdings: 105

Affinity Asset Advisors, LLC disclosed 105 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $1.9B and a quarterly turnover rate of 77.9%.

Browse other institutions with $1B to $10B AUM Browse other institutions starting with "A"

Personality snowflake

Concentration: 10.41
Portfolio Stability: 77.88
Momentum/Contrarian: 100
Sector conviction: 100
Diversification: 100
Sizing Uniformity: 86.97

Recent moves

Add ERAS
+37.2%　$72.1M
Trim WVE
-48.1%　-$35.7M
Add 260
+133.1%　$40.6M
Add ROIV
+64.7%　$40.7M
Add XENE
+34.0%　$41.4M
Trim ABVX
-19.8%　-$23.0M

Holdings Map

New buyAddUnchangedTrim

Top 10 holdings by weight

Full holdings list this quarter

Showing top 103 holdings (of 105 total)

#	Ticker	Issuer	Asset Subclass	Weight	Weight Change	Shares Change
1	SPY	Ss Spdr S&p 500 ETF Trust-us	ETF-Large Cap & Growth	6.72%	+6.72%	NEW
2	APGE	Apogee Therapeutics INC	Stock-Other	5.59%	+0.28%	+4.05%
3	XENE	Xenon Pharmaceuticals INC	Stock-Other	5.03%	+1.84%	+34.00%
4	ERAS	Erasca INC	Stock-Other	4.47%	+3.64%	+37.18%
5	INSM	Insmed INC	Stock-Healthcare	4.05%	—	+6.67%
6	ROIV	Roivant Sciences Ltd.	Stock-Healthcare	4.01%	+1.91%	+64.71%
7	SYRE	Spyre Therapeutics INC	Stock-Other	3.33%	+0.66%	-10.71%
8	260	Centessa Pharmaceuticals-adr	Stock-Other	2.87%	+2.01%	+133.12%
9	PRAX	Praxis Precision Medicines I	Stock-Other	2.83%	—	-8.11%
10	ANAB	Anaptysbio INC	Stock-Other	2.69%	+1.46%	+111.38%
11	ALKS	Alkermes plc	Stock-Healthcare	2.47%	+0.88%	+35.00%
12	CYTK	Cytokinetics INC	Stock-Healthcare	2.38%	—	-12.44%
13	ABVX	Abivax Sa-adr	Stock-Other	2.33%	-1.55%	-19.80%
14	TEVA	Teva Pharmaceutical-sp Adr	Stock-Healthcare	2.18%	—	—
15	ACLXGBX	Arcellx INC	Stock-Other	2.15%	+0.20%	-30.73%
16	MRNA	Moderna INC	Stock-Healthcare	2.10%	+2.10%	NEW
17	DNTH	Dianthus Therapeutics INC	Stock-Other	1.73%	+1.46%	+247.83%
18	NUVL	Nuvalent Inc-a	Stock-Other	1.59%	—	-7.02%
19	430	Terns Pharmaceuticals INC	Stock-Other	1.53%	+0.26%	+2.30%
20	LXEO	Lexeo Therapeutics INC	Stock-Other	1.50%	—	+57.82%
21	COGT	Cogent Biosciences INC	Stock-Other	1.49%	+0.78%	+114.29%
22	MDGL	Madrigal Pharmaceuticals INC	Stock-Healthcare	1.49%	+0.46%	+76.67%
23	STRO	Sutro Biopharma INC	Stock-Other	1.38%	+0.89%	+42.91%
24	FBRX	Forte Biosciences INC	Stock-Other	1.35%	—	—
25	ORKA	Oruka Therapeutics INC	Stock-Other	1.27%	—	-37.72%
26	TRVI	Trevi Therapeutics INC	Stock-Other	1.23%	—	-6.98%
27	OVID	Ovid Therapeutics INC	Stock-Other	1.22%	+0.56%	+48.76%
28	ELVN	Enliven Therapeutics INC	Stock-Other	1.19%	+1.19%	NEW
29	ASND	Ascendis Pharma A/S	Stock-Other	1.12%	+0.76%	+216.67%
30	MLYS	Mineralys Therapeutics INC	Stock-Other	1.05%	—	+2.74%
31	AVTX	Avalo Therapeutics INC	Stock-Other	1.03%	—	+27.57%
32	RVMD	Revolution Medicines INC	Stock-Healthcare	1.00%	+0.55%	+100.00%
33	BMY	Bristol-myers Squibb Co	Stock-Healthcare	0.94%	+0.94%	NEW
34	PTGX	Protagonist Therapeutics INC	Stock-Other	0.94%	—	—
35	CLDX	Celldex Therapeutics INC	Stock-Other	0.82%	—	+42.86%
36	✓	Zura Bio LTD	Stock-Other	0.79%	—	+41.39%
37	NRIX	Nurix Therapeutics INC	Stock-Other	0.77%	—	—
38	SVRA	Savara INC	Stock-Other	0.71%	—	-10.19%
39	OMER 9.5 06-15-29	Omeros CORP	Stock-Other	0.68%	—	—
40	CATX	Perspective Therapeutics INC	Stock-Other	0.68%	+0.63%	+954.86%
41	✓	Helix Acquisition CORP Iii	Stock-Other	0.66%	+0.66%	NEW
42	ARWR	Arrowhead Pharmaceuticals In	Stock-Healthcare	0.65%	+0.39%	+185.71%
43	DMRA	Damora Therapeutics INC	Stock-Other	0.60%	+0.60%	NEW
44	EPRX	Eupraxia Pharmaceuticals INC	Stock-Other	0.59%	+0.46%	+429.67%
45	ANRO	Alto Neuroscience INC	Stock-Other	0.58%	+0.58%	NEW
46	BBIO	Bridgebio Pharma INC	Stock-Healthcare	0.58%	-0.81%	-53.13%
47	CGEM	Cullinan Therapeutics INC	Stock-Other	0.57%	-0.57%	-59.56%
48	BLTE	Belite Bio INC - Adr	Stock-Other	0.54%	+0.36%	+225.00%
49	WVE	Wave Life Sciences Ltd.	Stock-Other	0.52%	-2.10%	-48.08%
50	VERA	Vera Therapeutics INC	Stock-Other	0.52%	—	—

1–50 of 103

Portfolio Performance

Performance for Q3 2026

+21.4%

Performance Last 4 Quarters

+94.4%

Based on 77% of reported portfolio value with available pricing

Stdev: +25.3%
Beta: +0.51
Alpha: +17%
Max Drawdown: -32.8%
Annualized Perf: +25.8%
Batting Avg vs S&P: +46.2%
Sortino: +1.97
Stutzer: +0.31
Treynor: +0.51
Sterling: +0.89
Calmar: +0.79
Information Ratio: +0.32
Tracking Error: +25.2%
Stdev Down: +13.3%
Winning Months %: +61.5%
Losing Months %: +38.5%
Best 12 Months: +98.2%
Worst 12 Months: -24.9%
Efficiency Ratio: +0.43
Sharpe: +1.03
Stdev Sectors: 0%
Skewness: +0.14
Kurtosis: -0.33
Upside Potential: +3.59

Reported value over time

Sector allocation

Sector allocation over time

Quarterly history

Period	Holdings	Total value	Stability	Top holdings
2026-03-31	105	$1.9B	78	1SPY 2APGE 3XENE Top holdings2026-03-31 1.SPY 2.APGE 3.XENE 4.ERAS 5.INSM 6.ROIV 7.SYRE 8.260 9.PRAX 10.ANAB
2025-12-31	95	$1.8B	96	1XBI 2APGE 3INSM Top holdings2025-12-31 1.XBI 2.APGE 3.INSM 4.ABVX 5.IBB 6.VTYXUSD 7.XENE 8.PRAX 9.CYTK 10.AMGN
2025-09-30	96	$1.1B	100	1INSM 2VRNA 3SPY Top holdings2025-09-30 1.INSM 2.VRNA 3.SPY 4.XENE 5.MDGL 6.APGE 7.ACLXGBX 8.ALKS 9.NUVL 10.ABVX
2025-06-30	91	$732.2M	0	1VRNA 2INSM 3XENE Top holdings2025-06-30 1.VRNA 2.INSM 3.XENE 4.ACLXGBX 5.2655787D 6.NUVL 7.APGE 8.ALKS 9.EXEL 10.PTGX
2025-03-31	98	$1.0B	100	1SPY 2IWM 3XENE Top holdings2025-03-31 1.SPY 2.IWM 3.XENE 4.APGE 5.XBI 6.VRNA 7.ACLXGBX 8.ALKS 9.NUVL 10.PTGX
2024-12-31	85	$746.0M	0	1XBI 2XENE 3APGE Top holdings2024-12-31 1.XBI 2.XENE 3.APGE 4.ACLXGBX 5.ALKS 6.TEVA 7.VRNA 8.MDGL 9.CRNX 10.NUVL
2024-09-30	86	$732.8M	0	1XENE 2TEVA 3FLNA Top holdings2024-09-30 1.XENE 2.TEVA 3.FLNA 4.APGE 5.NUVL 6.ACLXGBX 7.ALKS 8.MDGL 9.CRNX 10.NRIX
2024-06-30	98	$867.5M	0	1SPY 2TEVA 3XENE Top holdings2024-06-30 1.SPY 2.TEVA 3.XENE 4.APGE 5.MDGL 6.CERE1EUR 7.ACLXGBX 8.CRNX 9.NRIX 10.CLDX
2024-03-31	95	$807.8M	0	1XBI 2TEVA 3MRNA Top holdings2024-03-31 1.XBI 2.TEVA 3.MRNA 4.APGE 5.XENE 6.MDGL 7.CRNX 8.AUTL 9.CLDX 10.ACLXGBX
2023-12-31	82	$547.5M	0	1IMGNEUR 2TEVA 3CERE1EUR Top holdings2023-12-31 1.IMGNEUR 2.TEVA 3.CERE1EUR 4.CBAYUSD 5.MDGL 6.XENE 7.BBIO 2.5 03-15-27 8.CRNX 9.ACLXGBX 10.LIANY
2023-09-30	81	$355.5M	0	1TEVA 2APGE3G31249 Top holdings2023-09-30 1.TEVA 2.APGE 3.G31249 4.CBAYUSD 5.IMVT 6.BBIO 2.5 03-15-27 7.CERE1EUR 8.ACLXGBX 9.CRNX 10.MDGL
2023-06-30	70	$286.3M	0	1MDGL 2CERE1EUR3G31249 Top holdings2023-06-30 1.MDGL 2.CERE1EUR 3.G31249 4.290A 5.TEVA 6.MORFUSD 7.CBAYUSD 8.BIIB 9.VKTX 10.KURA
2023-03-31	74	$303.0M	0	1290A 2MDGL 3SPY Top holdings2023-03-31 1.290A 2.MDGL 3.SPY 4.74349U 5.MRK 6.VKTX 7.BBIO 8.CBAYUSD 9.CERE1EUR 10.VRNA
2022-12-31	63	$255.0M	0	1290A 2MDGL 3BMY Top holdings2022-12-31 1.290A 2.MDGL 3.BMY 4.G31249 5.VRNA 6.ASND 7.BMRN 8.74349U 9.VTYXUSD 10.MORFUSD
2022-09-30	64	$358.3M	0	1SPY 2SNY3G31249 Top holdings2022-09-30 1.SPY 2.SNY 3.G31249 4.290A 5.AZNN 6.GBTUSD 7.IWM 8.MDGL 9.LNTH 10.TVTX 2.5 09-15-25
2022-06-30	54	$237.2M	0	1G312492KURA 3290A Top holdings2022-06-30 1.G31249 2.KURA 3.290A 4.NARIUSD 5.LNTH 6.ASND 7.48576A 8.TVTX 2.5 09-15-25 9.LLY 10.NVAX
2022-03-31	59	$625.0M	0	1SPY 2SWTXUSD 3NARIUSD Top holdings2022-03-31 1.SPY 2.SWTXUSD 3.NARIUSD 4.MORFUSD 5.KURA 6.ASND 7.290A 8.PTGX 9.G31249 10.TVTX 2.5 09-15-25
2021-12-31	55	$275.4M	0	1MORFUSD 2SWTXUSD 3FLNA Top holdings2021-12-31 1.MORFUSD 2.SWTXUSD 3.FLNA 4.92731L 5.NARIUSD 6.ZNTL 7.ARNAEUR 8.290A 9.PTGX 10.BBIO
2021-09-30	73	$396.0M	0	1XBI 2SPY 3BBIO Top holdings2021-09-30 1.XBI 2.SPY 3.BBIO 4.92731L 5.MORFUSD 6.NARIUSD 7.KURA 8.SWTXUSD 9.CERE1EUR 10.OCUL
2021-06-30	69	$279.3M	100	1BBIO 2XBI 3ARKG Top holdings2021-06-30 1.BBIO 2.XBI 3.ARKG 4.MORFUSD 5.N2451R 6.92731L 7.NAUT 8.KURA 9.NARIUSD 10.ZNTL
2021-03-31	72	$294.5M	95	1SPY 2BBIO 3ARKG Top holdings2021-03-31 1.SPY 2.BBIO 3.ARKG 4.CRISEUR 5.MORFUSD 6.VRTX 7.92731L 8.KURA 9.G3166W 10.G31659
2020-12-31	62	$188.7M	—	1EIDXGBP 2SPY 3CRISEUR Top holdings2020-12-31 1.EIDXGBP 2.SPY 3.CRISEUR 4.BBIO 5.KURA 6.92731L 7.RCKT 8.XLRN 9.OCUL 10.CERE1EUR

Holding changes this quarter

Affinity Asset Advisors, LLC's most significant position changes for 2026-03-31: Sold out: Ss Spdr S&p Biotech ETF (XBI); New buy: Ss Spdr S&p 500 ETF Trust-us (SPY); Sold out: Ishares Biotechnology ETF (IBB); Sold out: Ventyx Biosciences INC (VTYXUSD); Sold out: Amgen INC (AMGN).

Position changes disclosed by Affinity Asset Advisors, LLC for the quarter ending 2026-03-31, including ticker, issuer, weight change, shares change, and action
#	Ticker	Issuer	Weight Change	Shares Change	Action
1	ERAS	Erasca INC	+3.6%	+37.18%	Add
2	260	Centessa Pharmaceuticals-adr	+2%	+133.12%	Add
3	ROIV	Roivant Sciences Ltd.	+1.9%	+64.71%	Add
4	XENE	Xenon Pharmaceuticals INC	+1.8%	+34.00%	Add
5	ANAB	Anaptysbio INC	+1.5%	+111.38%	Add
6	DNTH	Dianthus Therapeutics INC	+1.5%	+247.83%	Add
7	STRO	Sutro Biopharma INC	+0.9%	+42.91%	Add
8	ALKS	Alkermes plc	+0.9%	+35.00%	Add
9	COGT	Cogent Biosciences INC	+0.8%	+114.29%	Add
10	ASND	Ascendis Pharma A/S	+0.8%	+216.67%	Add
11	SYRE	Spyre Therapeutics INC	+0.7%	-10.71%	Trim
12	CATX	Perspective Therapeutics INC	+0.6%	+954.86%	Add
13	OVID	Ovid Therapeutics INC	+0.6%	+48.76%	Add
14	RVMD	Revolution Medicines INC	+0.6%	+100.00%	Add
15	MDGL	Madrigal Pharmaceuticals INC	+0.5%	+76.67%	Add
16	EPRX	Eupraxia Pharmaceuticals INC	+0.5%	+429.67%	Add
17	ARWR	Arrowhead Pharmaceuticals In	+0.4%	+185.71%	Add
18	COGT 1.625 11-15-31	Cogent Biosciences INC	+0.4%	+600.00%	Add
19	BLTE	Belite Bio INC - Adr	+0.4%	+225.00%	Add
20	APGE	Apogee Therapeutics INC	+0.3%	+4.05%	Add
21	430	Terns Pharmaceuticals INC	+0.3%	+2.30%	Add
22	ACLXGBX	Arcellx INC	+0.2%	-30.73%	Trim
23	✓	Establishment Labs Hldgs INC	-0.5%	-50.00%	Trim
24	CGEM	Cullinan Therapeutics INC	-0.6%	-59.56%	Trim
25	TSHA	Taysha Gene Therapies INC	-0.8%	-69.70%	Trim
26	BBIO	Bridgebio Pharma INC	-0.8%	-53.13%	Trim
27	QURE	uniQure N.V.	-0.9%	-64.71%	Trim
28	ABVX	Abivax Sa-adr	-1.6%	-19.80%	Trim
29	WVE	Wave Life Sciences Ltd.	-2.1%	-48.08%	Trim
30	XBI	Ss Spdr S&p Biotech ETF	—	EXIT	Sold out
31	SPY	Ss Spdr S&p 500 ETF Trust-us	—	NEW	New buy
32	IBB	Ishares Biotechnology ETF	—	EXIT	Sold out
33	VTYXUSD	Ventyx Biosciences INC	—	EXIT	Sold out
34	AMGN	Amgen INC	—	EXIT	Sold out
35	MRNA	Moderna INC	—	NEW	New buy
36	XLV	Ss Health Care Select Sector	—	EXIT	Sold out
37	ELVN	Enliven Therapeutics INC	—	NEW	New buy
38	BMY	Bristol-myers Squibb Co	—	NEW	New buy
39	✓	Helix Acquisition CORP Iii	—	NEW	New buy
40	DMRA	Damora Therapeutics INC	—	NEW	New buy
41	ANRO	Alto Neuroscience INC	—	NEW	New buy
42	TVTX 2.25 03-01-29	Travere Therapeutics INC	—	EXIT	Sold out
43	TYRA	Tyra Biosciences INC	—	NEW	New buy
44	IBRX	Immunitybio INC	—	NEW	New buy
45	TNGX	Tango Therapeutics INC	—	EXIT	Sold out
46	KRRO	Korro Bio INC	—	NEW	New buy
47	RCUS	Arcus Biosciences INC	—	EXIT	Sold out
48	CRSP	CRISPR Therapeutics AG	—	NEW	New buy
49	SGP	Spyglass Pharma INC	—	NEW	New buy
50	NVO	Novo-nordisk A/s-spons Adr	—	NEW	New buy

FAQ

What is Affinity Asset Advisors, LLC and what type of investor is it?

Affinity Asset Advisors, LLC is a investment manager that files SEC Form 13F quarterly, disclosing its U.S. public equity holdings to regulators. As of the most recent reporting period (2026-03-31), the firm manages a tracked equity portfolio valued at approximately $1.9B, spread across 105 disclosed positions.

What are Affinity Asset Advisors, LLC's largest equity positions?

Based on the latest 13F filing, Affinity Asset Advisors, LLC's top holdings by market value are: 1. Ss Spdr S&p 500 ETF Trust-us (SPY) — $130.1M (6.7%) 2. Apogee Therapeutics INC (APGE) — $108.2M (5.6%) 3. Xenon Pharmaceuticals INC (XENE) — $97.4M (5.0%) 4. Erasca INC (ERAS) — $86.6M (4.5%) 5. Insmed INC (INSM) — $78.5M (4.0%)

What changes did Affinity Asset Advisors, LLC make in its most recent portfolio filing?

In the latest reported quarter, Affinity Asset Advisors, LLC made 50 notable position adjustments: 13 new positions were initiated, 20 existing holdings were added to, 9 positions were partially reduced, and 8 were completely exited. The largest of these moves: Sold out: Ss Spdr S&p Biotech ETF (XBI); New buy: Ss Spdr S&p 500 ETF Trust-us (SPY); Sold out: Ishares Biotechnology ETF (IBB); Sold out: Ventyx Biosciences INC (VTYXUSD); Sold out: Amgen INC (AMGN)

What sectors does Affinity Asset Advisors, LLC focus on?

Affinity Asset Advisors, LLC is concentrated in the following sectors based on its current disclosed equity portfolio: • Health Care: 100.0%

Peer Institutions

Institutions with a similar AUM

Tt International

CIK 0001483532

Total reported value

$1.9B

60 stks

2020-09-30

Stale — no recent filing

Concentration55.5

Portfolio Stability80.6

Sector conviction100.0

AUM within 0.0% of this institution

View detail

Community Trust & Investment Co

CIK 0001047142

Total reported value

$1.9B

262 stks

2026-06-30

Concentration10.8

Portfolio Stability17.7

Sector conviction53.8

AUM within 0.1% of this institution

View detail

Foster & Motley INC

CIK 0001163902

Total reported value

$1.9B

395 stks

2026-03-31

Concentration6.0

Portfolio Stability11.8

Sector conviction64.7

AUM within 0.1% of this institution

View detail

Similar Holdings Style

Institutions with overlapping top holdings

Venrock Adviser, LLC

CIK 0001615982

Total reported value

$2.7B

33 stks

2026-03-31

Concentration41.5

Portfolio Stability41.3

Sector conviction0.0

2 of the top 5 holdings overlap, including Apogee Therapeutics INC

View detail

Brown, Lisle/cummings, INC.

CIK 0000014745

Total reported value

$400.4M

1,021 stks

2026-03-31

Concentration5.0

Portfolio Stability13.4

Sector conviction47.9

1 of the top 5 holdings overlap, including Ss Spdr S&p 500 ETF Trust-us

View detail

Synovus Financial CORP

CIK 0000018349

Total reported value

$8.7B

1,549 stks

2025-09-30

Stale — no recent filing

Concentration10.2

Portfolio Stability22.0

Sector conviction57.0

1 of the top 5 holdings overlap, including Ss Spdr S&p 500 ETF Trust-us

View detail

Affinity Asset Advisors, LLC — Full 13F Portfolio Breakdown

Diversified strategySector-focusedMomentum follower

Total reported value

$1.9B

Reporting period: 2026-03-31 · Number of holdings: 105

Affinity Asset Advisors, LLC disclosed 105 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $1.9B and a quarterly turnover rate of 77.9%.

Browse other institutions with $1B to $10B AUM Browse other institutions starting with "A"

Personality snowflake

Concentration: 10.41
Portfolio Stability: 77.88
Momentum/Contrarian: 100
Sector conviction: 100
Diversification: 100
Sizing Uniformity: 86.97

Recent moves

Add ERAS
+37.2%　$72.1M
Trim WVE
-48.1%　-$35.7M
Add 260
+133.1%　$40.6M
Add ROIV
+64.7%　$40.7M
Add XENE
+34.0%　$41.4M
Trim ABVX
-19.8%　-$23.0M

Holdings Map

New buyAddUnchangedTrim

Top 10 holdings by weight

Full holdings list this quarter

Showing top 103 holdings (of 105 total)

#	Ticker	Issuer	Asset Subclass	Weight	Weight Change	Shares Change
1	SPY	Ss Spdr S&p 500 ETF Trust-us	ETF-Large Cap & Growth	6.72%	+6.72%	NEW
2	APGE	Apogee Therapeutics INC	Stock-Other	5.59%	+0.28%	+4.05%
3	XENE	Xenon Pharmaceuticals INC	Stock-Other	5.03%	+1.84%	+34.00%
4	ERAS	Erasca INC	Stock-Other	4.47%	+3.64%	+37.18%
5	INSM	Insmed INC	Stock-Healthcare	4.05%	—	+6.67%
6	ROIV	Roivant Sciences Ltd.	Stock-Healthcare	4.01%	+1.91%	+64.71%
7	SYRE	Spyre Therapeutics INC	Stock-Other	3.33%	+0.66%	-10.71%
8	260	Centessa Pharmaceuticals-adr	Stock-Other	2.87%	+2.01%	+133.12%
9	PRAX	Praxis Precision Medicines I	Stock-Other	2.83%	—	-8.11%
10	ANAB	Anaptysbio INC	Stock-Other	2.69%	+1.46%	+111.38%
11	ALKS	Alkermes plc	Stock-Healthcare	2.47%	+0.88%	+35.00%
12	CYTK	Cytokinetics INC	Stock-Healthcare	2.38%	—	-12.44%
13	ABVX	Abivax Sa-adr	Stock-Other	2.33%	-1.55%	-19.80%
14	TEVA	Teva Pharmaceutical-sp Adr	Stock-Healthcare	2.18%	—	—
15	ACLXGBX	Arcellx INC	Stock-Other	2.15%	+0.20%	-30.73%
16	MRNA	Moderna INC	Stock-Healthcare	2.10%	+2.10%	NEW
17	DNTH	Dianthus Therapeutics INC	Stock-Other	1.73%	+1.46%	+247.83%
18	NUVL	Nuvalent Inc-a	Stock-Other	1.59%	—	-7.02%
19	430	Terns Pharmaceuticals INC	Stock-Other	1.53%	+0.26%	+2.30%
20	LXEO	Lexeo Therapeutics INC	Stock-Other	1.50%	—	+57.82%
21	COGT	Cogent Biosciences INC	Stock-Other	1.49%	+0.78%	+114.29%
22	MDGL	Madrigal Pharmaceuticals INC	Stock-Healthcare	1.49%	+0.46%	+76.67%
23	STRO	Sutro Biopharma INC	Stock-Other	1.38%	+0.89%	+42.91%
24	FBRX	Forte Biosciences INC	Stock-Other	1.35%	—	—
25	ORKA	Oruka Therapeutics INC	Stock-Other	1.27%	—	-37.72%
26	TRVI	Trevi Therapeutics INC	Stock-Other	1.23%	—	-6.98%
27	OVID	Ovid Therapeutics INC	Stock-Other	1.22%	+0.56%	+48.76%
28	ELVN	Enliven Therapeutics INC	Stock-Other	1.19%	+1.19%	NEW
29	ASND	Ascendis Pharma A/S	Stock-Other	1.12%	+0.76%	+216.67%
30	MLYS	Mineralys Therapeutics INC	Stock-Other	1.05%	—	+2.74%
31	AVTX	Avalo Therapeutics INC	Stock-Other	1.03%	—	+27.57%
32	RVMD	Revolution Medicines INC	Stock-Healthcare	1.00%	+0.55%	+100.00%
33	BMY	Bristol-myers Squibb Co	Stock-Healthcare	0.94%	+0.94%	NEW
34	PTGX	Protagonist Therapeutics INC	Stock-Other	0.94%	—	—
35	CLDX	Celldex Therapeutics INC	Stock-Other	0.82%	—	+42.86%
36	✓	Zura Bio LTD	Stock-Other	0.79%	—	+41.39%
37	NRIX	Nurix Therapeutics INC	Stock-Other	0.77%	—	—
38	SVRA	Savara INC	Stock-Other	0.71%	—	-10.19%
39	OMER 9.5 06-15-29	Omeros CORP	Stock-Other	0.68%	—	—
40	CATX	Perspective Therapeutics INC	Stock-Other	0.68%	+0.63%	+954.86%
41	✓	Helix Acquisition CORP Iii	Stock-Other	0.66%	+0.66%	NEW
42	ARWR	Arrowhead Pharmaceuticals In	Stock-Healthcare	0.65%	+0.39%	+185.71%
43	DMRA	Damora Therapeutics INC	Stock-Other	0.60%	+0.60%	NEW
44	EPRX	Eupraxia Pharmaceuticals INC	Stock-Other	0.59%	+0.46%	+429.67%
45	ANRO	Alto Neuroscience INC	Stock-Other	0.58%	+0.58%	NEW
46	BBIO	Bridgebio Pharma INC	Stock-Healthcare	0.58%	-0.81%	-53.13%
47	CGEM	Cullinan Therapeutics INC	Stock-Other	0.57%	-0.57%	-59.56%
48	BLTE	Belite Bio INC - Adr	Stock-Other	0.54%	+0.36%	+225.00%
49	WVE	Wave Life Sciences Ltd.	Stock-Other	0.52%	-2.10%	-48.08%
50	VERA	Vera Therapeutics INC	Stock-Other	0.52%	—	—

1–50 of 103

Portfolio Performance

Performance for Q3 2026

+21.4%

Performance Last 4 Quarters

+94.4%

Based on 77% of reported portfolio value with available pricing

Stdev: +25.3%
Beta: +0.51
Alpha: +17%
Max Drawdown: -32.8%
Annualized Perf: +25.8%
Batting Avg vs S&P: +46.2%
Sortino: +1.97
Stutzer: +0.31
Treynor: +0.51
Sterling: +0.89
Calmar: +0.79
Information Ratio: +0.32
Tracking Error: +25.2%
Stdev Down: +13.3%
Winning Months %: +61.5%
Losing Months %: +38.5%
Best 12 Months: +98.2%
Worst 12 Months: -24.9%
Efficiency Ratio: +0.43
Sharpe: +1.03
Stdev Sectors: 0%
Skewness: +0.14
Kurtosis: -0.33
Upside Potential: +3.59

Reported value over time

Sector allocation

Sector allocation over time

Quarterly history

Period	Holdings	Total value	Stability	Top holdings
2026-03-31	105	$1.9B	78	1SPY 2APGE 3XENE Top holdings2026-03-31 1.SPY 2.APGE 3.XENE 4.ERAS 5.INSM 6.ROIV 7.SYRE 8.260 9.PRAX 10.ANAB
2025-12-31	95	$1.8B	96	1XBI 2APGE 3INSM Top holdings2025-12-31 1.XBI 2.APGE 3.INSM 4.ABVX 5.IBB 6.VTYXUSD 7.XENE 8.PRAX 9.CYTK 10.AMGN
2025-09-30	96	$1.1B	100	1INSM 2VRNA 3SPY Top holdings2025-09-30 1.INSM 2.VRNA 3.SPY 4.XENE 5.MDGL 6.APGE 7.ACLXGBX 8.ALKS 9.NUVL 10.ABVX
2025-06-30	91	$732.2M	0	1VRNA 2INSM 3XENE Top holdings2025-06-30 1.VRNA 2.INSM 3.XENE 4.ACLXGBX 5.2655787D 6.NUVL 7.APGE 8.ALKS 9.EXEL 10.PTGX
2025-03-31	98	$1.0B	100	1SPY 2IWM 3XENE Top holdings2025-03-31 1.SPY 2.IWM 3.XENE 4.APGE 5.XBI 6.VRNA 7.ACLXGBX 8.ALKS 9.NUVL 10.PTGX
2024-12-31	85	$746.0M	0	1XBI 2XENE 3APGE Top holdings2024-12-31 1.XBI 2.XENE 3.APGE 4.ACLXGBX 5.ALKS 6.TEVA 7.VRNA 8.MDGL 9.CRNX 10.NUVL
2024-09-30	86	$732.8M	0	1XENE 2TEVA 3FLNA Top holdings2024-09-30 1.XENE 2.TEVA 3.FLNA 4.APGE 5.NUVL 6.ACLXGBX 7.ALKS 8.MDGL 9.CRNX 10.NRIX
2024-06-30	98	$867.5M	0	1SPY 2TEVA 3XENE Top holdings2024-06-30 1.SPY 2.TEVA 3.XENE 4.APGE 5.MDGL 6.CERE1EUR 7.ACLXGBX 8.CRNX 9.NRIX 10.CLDX
2024-03-31	95	$807.8M	0	1XBI 2TEVA 3MRNA Top holdings2024-03-31 1.XBI 2.TEVA 3.MRNA 4.APGE 5.XENE 6.MDGL 7.CRNX 8.AUTL 9.CLDX 10.ACLXGBX
2023-12-31	82	$547.5M	0	1IMGNEUR 2TEVA 3CERE1EUR Top holdings2023-12-31 1.IMGNEUR 2.TEVA 3.CERE1EUR 4.CBAYUSD 5.MDGL 6.XENE 7.BBIO 2.5 03-15-27 8.CRNX 9.ACLXGBX 10.LIANY
2023-09-30	81	$355.5M	0	1TEVA 2APGE3G31249 Top holdings2023-09-30 1.TEVA 2.APGE 3.G31249 4.CBAYUSD 5.IMVT 6.BBIO 2.5 03-15-27 7.CERE1EUR 8.ACLXGBX 9.CRNX 10.MDGL
2023-06-30	70	$286.3M	0	1MDGL 2CERE1EUR3G31249 Top holdings2023-06-30 1.MDGL 2.CERE1EUR 3.G31249 4.290A 5.TEVA 6.MORFUSD 7.CBAYUSD 8.BIIB 9.VKTX 10.KURA
2023-03-31	74	$303.0M	0	1290A 2MDGL 3SPY Top holdings2023-03-31 1.290A 2.MDGL 3.SPY 4.74349U 5.MRK 6.VKTX 7.BBIO 8.CBAYUSD 9.CERE1EUR 10.VRNA
2022-12-31	63	$255.0M	0	1290A 2MDGL 3BMY Top holdings2022-12-31 1.290A 2.MDGL 3.BMY 4.G31249 5.VRNA 6.ASND 7.BMRN 8.74349U 9.VTYXUSD 10.MORFUSD
2022-09-30	64	$358.3M	0	1SPY 2SNY3G31249 Top holdings2022-09-30 1.SPY 2.SNY 3.G31249 4.290A 5.AZNN 6.GBTUSD 7.IWM 8.MDGL 9.LNTH 10.TVTX 2.5 09-15-25
2022-06-30	54	$237.2M	0	1G312492KURA 3290A Top holdings2022-06-30 1.G31249 2.KURA 3.290A 4.NARIUSD 5.LNTH 6.ASND 7.48576A 8.TVTX 2.5 09-15-25 9.LLY 10.NVAX
2022-03-31	59	$625.0M	0	1SPY 2SWTXUSD 3NARIUSD Top holdings2022-03-31 1.SPY 2.SWTXUSD 3.NARIUSD 4.MORFUSD 5.KURA 6.ASND 7.290A 8.PTGX 9.G31249 10.TVTX 2.5 09-15-25
2021-12-31	55	$275.4M	0	1MORFUSD 2SWTXUSD 3FLNA Top holdings2021-12-31 1.MORFUSD 2.SWTXUSD 3.FLNA 4.92731L 5.NARIUSD 6.ZNTL 7.ARNAEUR 8.290A 9.PTGX 10.BBIO
2021-09-30	73	$396.0M	0	1XBI 2SPY 3BBIO Top holdings2021-09-30 1.XBI 2.SPY 3.BBIO 4.92731L 5.MORFUSD 6.NARIUSD 7.KURA 8.SWTXUSD 9.CERE1EUR 10.OCUL
2021-06-30	69	$279.3M	100	1BBIO 2XBI 3ARKG Top holdings2021-06-30 1.BBIO 2.XBI 3.ARKG 4.MORFUSD 5.N2451R 6.92731L 7.NAUT 8.KURA 9.NARIUSD 10.ZNTL
2021-03-31	72	$294.5M	95	1SPY 2BBIO 3ARKG Top holdings2021-03-31 1.SPY 2.BBIO 3.ARKG 4.CRISEUR 5.MORFUSD 6.VRTX 7.92731L 8.KURA 9.G3166W 10.G31659
2020-12-31	62	$188.7M	—	1EIDXGBP 2SPY 3CRISEUR Top holdings2020-12-31 1.EIDXGBP 2.SPY 3.CRISEUR 4.BBIO 5.KURA 6.92731L 7.RCKT 8.XLRN 9.OCUL 10.CERE1EUR

Holding changes this quarter

Position changes disclosed by Affinity Asset Advisors, LLC for the quarter ending 2026-03-31, including ticker, issuer, weight change, shares change, and action
#	Ticker	Issuer	Weight Change	Shares Change	Action
1	ERAS	Erasca INC	+3.6%	+37.18%	Add
2	260	Centessa Pharmaceuticals-adr	+2%	+133.12%	Add
3	ROIV	Roivant Sciences Ltd.	+1.9%	+64.71%	Add
4	XENE	Xenon Pharmaceuticals INC	+1.8%	+34.00%	Add
5	ANAB	Anaptysbio INC	+1.5%	+111.38%	Add
6	DNTH	Dianthus Therapeutics INC	+1.5%	+247.83%	Add
7	STRO	Sutro Biopharma INC	+0.9%	+42.91%	Add
8	ALKS	Alkermes plc	+0.9%	+35.00%	Add
9	COGT	Cogent Biosciences INC	+0.8%	+114.29%	Add
10	ASND	Ascendis Pharma A/S	+0.8%	+216.67%	Add
11	SYRE	Spyre Therapeutics INC	+0.7%	-10.71%	Trim
12	CATX	Perspective Therapeutics INC	+0.6%	+954.86%	Add
13	OVID	Ovid Therapeutics INC	+0.6%	+48.76%	Add
14	RVMD	Revolution Medicines INC	+0.6%	+100.00%	Add
15	MDGL	Madrigal Pharmaceuticals INC	+0.5%	+76.67%	Add
16	EPRX	Eupraxia Pharmaceuticals INC	+0.5%	+429.67%	Add
17	ARWR	Arrowhead Pharmaceuticals In	+0.4%	+185.71%	Add
18	COGT 1.625 11-15-31	Cogent Biosciences INC	+0.4%	+600.00%	Add
19	BLTE	Belite Bio INC - Adr	+0.4%	+225.00%	Add
20	APGE	Apogee Therapeutics INC	+0.3%	+4.05%	Add
21	430	Terns Pharmaceuticals INC	+0.3%	+2.30%	Add
22	ACLXGBX	Arcellx INC	+0.2%	-30.73%	Trim
23	✓	Establishment Labs Hldgs INC	-0.5%	-50.00%	Trim
24	CGEM	Cullinan Therapeutics INC	-0.6%	-59.56%	Trim
25	TSHA	Taysha Gene Therapies INC	-0.8%	-69.70%	Trim
26	BBIO	Bridgebio Pharma INC	-0.8%	-53.13%	Trim
27	QURE	uniQure N.V.	-0.9%	-64.71%	Trim
28	ABVX	Abivax Sa-adr	-1.6%	-19.80%	Trim
29	WVE	Wave Life Sciences Ltd.	-2.1%	-48.08%	Trim
30	XBI	Ss Spdr S&p Biotech ETF	—	EXIT	Sold out
31	SPY	Ss Spdr S&p 500 ETF Trust-us	—	NEW	New buy
32	IBB	Ishares Biotechnology ETF	—	EXIT	Sold out
33	VTYXUSD	Ventyx Biosciences INC	—	EXIT	Sold out
34	AMGN	Amgen INC	—	EXIT	Sold out
35	MRNA	Moderna INC	—	NEW	New buy
36	XLV	Ss Health Care Select Sector	—	EXIT	Sold out
37	ELVN	Enliven Therapeutics INC	—	NEW	New buy
38	BMY	Bristol-myers Squibb Co	—	NEW	New buy
39	✓	Helix Acquisition CORP Iii	—	NEW	New buy
40	DMRA	Damora Therapeutics INC	—	NEW	New buy
41	ANRO	Alto Neuroscience INC	—	NEW	New buy
42	TVTX 2.25 03-01-29	Travere Therapeutics INC	—	EXIT	Sold out
43	TYRA	Tyra Biosciences INC	—	NEW	New buy
44	IBRX	Immunitybio INC	—	NEW	New buy
45	TNGX	Tango Therapeutics INC	—	EXIT	Sold out
46	KRRO	Korro Bio INC	—	NEW	New buy
47	RCUS	Arcus Biosciences INC	—	EXIT	Sold out
48	CRSP	CRISPR Therapeutics AG	—	NEW	New buy
49	SGP	Spyglass Pharma INC	—	NEW	New buy
50	NVO	Novo-nordisk A/s-spons Adr	—	NEW	New buy